A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Day One Biopharmaceuticals, Inc.
- Study ID
- NCT05377996
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Adenoid Cystic Carcinoma
- Breast Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
- Triple Negative Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Emi-Le — DRUGEmi-Le will be administered through a vein in your arm or port catheter (intravenously)
Study Details
A Study of Emi-Le in Participants with Solid Tumors
Key Dates
- First listed
- May 17, 2022
- Start date
- Aug 15, 2022
- Status verified
- Jun 2026
- Primary completion
- Feb 28, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 360 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Emi-LeSingle arm Emi-Le alone (monotherapy)
Primary Outcome Measure
Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with Emi-Le during the first cycle of treatment (Dose Escalation) [ Time Frame: 17 months ]
Central Contacts
- Day One Clinical Trials Information1-650-484-0899
Locations (26)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Comprehensive Cancer Center | Phoenix | Arizona | 85054 | Felipe Batalini, MD Felipe Batalini, MD (PRINCIPAL_INVESTIGATOR) |
| UC Irvine Health-Chao Family Comprehensive Cancer Center | Orange | California | 92868 | Ritesh Parajuli Ritesh Parajuli (PRINCIPAL_INVESTIGATOR) |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | Laura Huppert, MD Laura Huppert, MD (PRINCIPAL_INVESTIGATOR) |
| UCLA David Geffen School of Medicine, Division of Hematology/Oncology | Santa Monica | California | 90404 | Nicholas McAndrew, MD Nicholas McAndrew, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | Pooja Advani, MD Pooja Advani, MD (PRINCIPAL_INVESTIGATOR) |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Judy Wang Judy Wang (PRINCIPAL_INVESTIGATOR) |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Hyo Han, MD Hyo Han, MD (PRINCIPAL_INVESTIGATOR) |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | Kevin Kalinsky, MD |
| Northwestern University | Chicago | Illinois | 60611 | Patricia Robinson, MD Patricia Robinson, MD (PRINCIPAL_INVESTIGATOR) |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Gerburg Wulf, MD Gerburg Wulf, MD (PRINCIPAL_INVESTIGATOR) |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Antonio Giordano, MD, PhD |
| Henry Ford Health Hospital | Detroit | Michigan | 48202 | Amy Weise, MD |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | Roberto Leon-Ferre, MD Roberto Leon-Ferre, MD (PRINCIPAL_INVESTIGATOR) |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | Liawaty Ho, MD Liawaty Ho, MD (PRINCIPAL_INVESTIGATOR) |
| ICHAN School of Medicine at Mount Sinai | New York | New York | 10029 | Amy Tiersten Amy Tiersten (PRINCIPAL_INVESTIGATOR) |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Nour Abuhadra, MD |
| New York University Langone Health | New York | New York | 10016 | Nancy Chan, MD |
| Stephenson Cancer Center Oklahoma University Health | Oklahoma City | Oklahoma | 73104 | Debra Richardson, MD Debra Richardson, MD (PRINCIPAL_INVESTIGATOR) |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | David C. Starks, MD David C. Starks, MD (PRINCIPAL_INVESTIGATOR) |
| Sarah Cannon Research Institute (SCRI) | Nashville | Tennessee | 37203 | Erika P Hamilton, MD |
| Texas Oncology, P.A. | Dallas | Texas | 75251 | Joyce O'Shaughnessy, MD (PRINCIPAL_INVESTIGATOR) |
| MD Anderson | Houston | Texas | 77030 | Funda Meric-Bernstam Funda Meric-Bernstam (PRINCIPAL_INVESTIGATOR) |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | Kristen Kelley, MD Kristen Kelley, MD (PRINCIPAL_INVESTIGATOR) |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Alex Spira, MD, PhD |
| Fred Hutchinson Cancer Center | Seattle | Washington | 09109 | Jennifer Specht, MD |
| Summit Cancer Centers | Spokane | Washington | 99208 | Arvind Chaudhry, MD, PhD |
Find similar trials in Phoenix, AZ
By condition
By research site
Mayo Clinic Comprehensive Cancer Center· Phoenix, AZUC Irvine Health-Chao Family Comprehensive Cancer Center· Orange, CAUCSF Helen Diller Family Comprehensive Cancer Center· San Francisco, CAUCLA David Geffen School of Medicine, Division of Hematology/Oncology· Santa Monica, CAMayo Clinic - Jacksonville· Jacksonville, FLFlorida Cancer Specialists· Sarasota, FL
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA MutationsRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast CancerRecruiting · Northwestern University · Chicago, Illinois